Identification

Name
Rescinnamine
Accession Number
DB01180  (APRD00112)
Type
Small Molecule
Groups
Approved
Description

Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from Rauwolfia serpentina and other species of Rauwolfia. [Wikipedia]

Structure
Thumb
Synonyms
  • 3,4,5-Trimethoxycinnamoyl methyl reserpate
  • Rescinnamine
  • Trimethoxy cinnamoyl reserpate de methyl
  • Tsuruselpi S
International/Other Brands
Tsuruselpi S
Categories
UNII
Q6W1F7DJ2D
CAS number
24815-24-5
Weight
Average: 634.716
Monoisotopic: 634.289030952
Chemical Formula
C35H42N2O9
InChI Key
SZLZWPPUNLXJEA-QEGASFHISA-N
InChI
InChI=1S/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1
IUPAC Name
methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-{[3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy}-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4(9),5,7-tetraene-19-carboxylate
SMILES
[H][C@]12C[C@@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2

Pharmacology

Indication

For the treatment of hypertension.

Pharmacodynamics

Used to treat hypertension. Rescinnamine inhibits angiotensin-converting enzyme. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex and general vasoconstriction, both of which lead to increases vascular resistance. By inhibiting angiotensin II, aldosterone reabsorption is decreased as well as vasoconstriction. This combined effect serves to decrease blood pressure.

Mechanism of action

Rescinnamine Binds to and inhibits the angiotensin converting enzyme. Rescinnamine competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Rescinnamine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Rescinnamine.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Rescinnamine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Rescinnamine.Approved, Investigational
AcemetacinThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Rescinnamine.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Rescinnamine.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Rescinnamine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Rescinnamine.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Rescinnamine.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Rescinnamine.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Rescinnamine.Approved
AloxiprinThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Aloxiprin.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Rescinnamine.Approved, Withdrawn
AmbrisentanRescinnamine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineRescinnamine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Rescinnamine.Approved
Aminosalicylic AcidThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Aminosalicylic Acid.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Rescinnamine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Rescinnamine.Approved, Illicit, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Rescinnamine.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Rescinnamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Rescinnamine.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Rescinnamine.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Rescinnamine.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Rescinnamine.Approved, Investigational, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Rescinnamine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Rescinnamine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Rescinnamine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Rescinnamine.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Rescinnamine is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Rescinnamine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Rescinnamine.Approved, Investigational
AzosemideAzosemide may increase the hypotensive activities of Rescinnamine.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Rescinnamine.Approved, Investigational
BarnidipineRescinnamine may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Rescinnamine.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Rescinnamine.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Rescinnamine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Rescinnamine.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Rescinnamine.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Rescinnamine.Withdrawn
BenzthiazideThe risk or severity of hypotension can be increased when Benzthiazide is combined with Rescinnamine.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Rescinnamine.Approved
BepridilBepridil may increase the hypotensive activities of Rescinnamine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Rescinnamine.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Rescinnamine.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Rescinnamine.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Rescinnamine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Rescinnamine.Approved
BosentanBosentan may increase the hypotensive activities of Rescinnamine.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Rescinnamine.Investigational
BretyliumBretylium may increase the hypotensive activities of Rescinnamine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Rescinnamine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Rescinnamine.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Rescinnamine.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Rescinnamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Rescinnamine.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Rescinnamine.Experimental
BumetanideBumetanide may increase the hypotensive activities of Rescinnamine.Approved
BupranololBupranolol may increase the hypotensive activities of Rescinnamine.Approved
CadralazineCadralazine may increase the hypotensive activities of Rescinnamine.Experimental
CafedrineCafedrine may increase the hypotensive activities of Rescinnamine.Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Rescinnamine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Rescinnamine.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Rescinnamine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Rescinnamine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Rescinnamine.Approved
Carbaspirin calciumThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Rescinnamine.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Rescinnamine.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Rescinnamine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Rescinnamine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Rescinnamine.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Rescinnamine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Rescinnamine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Rescinnamine.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Rescinnamine.Approved
CicletanineCicletanine may increase the hypotensive activities of Rescinnamine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Rescinnamine.Approved
CiprofloxacinThe risk or severity of ventricular arrhythmias can be increased when Rescinnamine is combined with Ciprofloxacin.Approved, Investigational
ClonidineClonidine may increase the hypotensive activities of Rescinnamine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Rescinnamine.Approved
CloranololCloranolol may increase the hypotensive activities of Rescinnamine.Experimental
CryptenamineCryptenamine may increase the hypotensive activities of Rescinnamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Rescinnamine.Approved, Investigational
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Rescinnamine.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Rescinnamine.Approved
DapagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Rescinnamine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Rescinnamine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Rescinnamine.Approved, Investigational
DelaprilDelapril may increase the hypotensive activities of Rescinnamine.Experimental
DersalazineThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Dersalazine.Investigational
DeserpidineDeserpidine may increase the hypotensive activities of Rescinnamine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Rescinnamine.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Rescinnamine.Approved, Vet Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Rescinnamine.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Rescinnamine.Experimental
DiflunisalThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Diflunisal.Approved, Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Rescinnamine.Approved, Investigational
DipyridamoleDipyridamole may increase the antihypertensive activities of Rescinnamine.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Rescinnamine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Rescinnamine.Approved
DrospirenoneRescinnamine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Rescinnamine.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Rescinnamine.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Rescinnamine.Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
EmpagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Empagliflozin is combined with Rescinnamine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Rescinnamine.Approved
EndralazineEndralazine may increase the hypotensive activities of Rescinnamine.Experimental
EpanololEpanolol may increase the hypotensive activities of Rescinnamine.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Rescinnamine.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Rescinnamine.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Rescinnamine.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Rescinnamine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Rescinnamine.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Rescinnamine.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Rescinnamine.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Rescinnamine.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Rescinnamine.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Rescinnamine.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Rescinnamine.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Rescinnamine.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Rescinnamine.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Rescinnamine.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Rescinnamine.Experimental
FelodipineFelodipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Rescinnamine.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Rescinnamine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Rescinnamine.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Rescinnamine.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Rescinnamine.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Rescinnamine.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Rescinnamine.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Rescinnamine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Rescinnamine.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Rescinnamine.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Rescinnamine.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Rescinnamine.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Rescinnamine.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Rescinnamine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Rescinnamine.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
GuacetisalThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Rescinnamine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Rescinnamine.Approved
GuanazodineRescinnamine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Rescinnamine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
GuanoclorRescinnamine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzRescinnamine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanRescinnamine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Rescinnamine.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Heparin.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Rescinnamine.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Rescinnamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Rescinnamine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Rescinnamine.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Rescinnamine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Rescinnamine.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Rescinnamine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Rescinnamine.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Rescinnamine.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Rescinnamine.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Rescinnamine.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Rescinnamine.Experimental
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Rescinnamine.Approved
IndenololIndenolol may increase the hypotensive activities of Rescinnamine.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Rescinnamine.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Rescinnamine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Rescinnamine.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Rescinnamine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Rescinnamine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Rescinnamine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Rescinnamine.Approved, Investigational
IronIron can cause a decrease in the absorption of Rescinnamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Rescinnamine.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Rescinnamine.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Rescinnamine.Experimental
KetanserinKetanserin may increase the hypotensive activities of Rescinnamine.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Rescinnamine.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Rescinnamine.Approved
LabetalolLabetalol may increase the hypotensive activities of Rescinnamine.Approved
LacidipineLacidipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Rescinnamine can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Rescinnamine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Rescinnamine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Rescinnamine.Approved
LinsidomineLinsidomine may increase the hypotensive activities of Rescinnamine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Rescinnamine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Rescinnamine.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Rescinnamine.Approved
LofexidineLofexidine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Rescinnamine.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Rescinnamine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Rescinnamine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Rescinnamine.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Rescinnamine.Approved, Investigational
MacitentanRescinnamine may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Rescinnamine.Approved
ManidipineManidipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Rescinnamine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Rescinnamine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Rescinnamine.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Rescinnamine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Rescinnamine.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Rescinnamine.Approved, Investigational, Withdrawn
MethoserpidineRescinnamine may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Rescinnamine.Approved
Methyl salicylateThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Rescinnamine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Rescinnamine.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Rescinnamine.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Rescinnamine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MetyrosineMetyrosine may increase the hypotensive activities of Rescinnamine.Approved
MibefradilMibefradil may increase the hypotensive activities of Rescinnamine.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Rescinnamine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Rescinnamine.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rescinnamine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Rescinnamine.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Rescinnamine.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MuzolimineMuzolimine may increase the hypotensive activities of Rescinnamine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Rescinnamine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rescinnamine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Rescinnamine.Approved
NadololNadolol may increase the hypotensive activities of Rescinnamine.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Rescinnamine.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Rescinnamine.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Rescinnamine.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Rescinnamine.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Rescinnamine.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Rescinnamine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Rescinnamine.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Rescinnamine.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Rescinnamine.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Rescinnamine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Rescinnamine.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Rescinnamine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
NitroaspirinThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Rescinnamine.Approved, Investigational
ObinutuzumabRescinnamine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Rescinnamine.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Rescinnamine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Rescinnamine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Rescinnamine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Rescinnamine.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Rescinnamine.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Rescinnamine.Approved
OxprenololOxprenolol may increase the hypotensive activities of Rescinnamine.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Rescinnamine.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Rescinnamine.Experimental, Nutraceutical
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Rescinnamine.Approved
PargylinePargyline may increase the hypotensive activities of Rescinnamine.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Rescinnamine.Approved, Investigational
Patent BlueThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Patent Blue.Approved
PenbutololPenbutolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Rescinnamine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Rescinnamine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Rescinnamine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Rescinnamine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Rescinnamine.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Rescinnamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Rescinnamine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Rescinnamine.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Rescinnamine.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rescinnamine.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Rescinnamine.Approved
PindololPindolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Rescinnamine.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Rescinnamine.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Rescinnamine.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Rescinnamine.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Rescinnamine.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Rescinnamine.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Rescinnamine.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Rescinnamine.Approved
PotassiumPotassium may increase the hyperkalemic activities of Rescinnamine.Approved, Investigational
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Rescinnamine.Approved
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Rescinnamine.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Rescinnamine.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Rescinnamine.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Rescinnamine.Approved
PregabalinThe risk or severity of angioedema can be increased when Rescinnamine is combined with Pregabalin.Approved, Illicit, Investigational
ProcaineProcaine may increase the hypotensive activities of Rescinnamine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Rescinnamine.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Rescinnamine.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Rescinnamine.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Rescinnamine.Experimental
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Rescinnamine.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Rescinnamine.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Rescinnamine.Approved
QuinineQuinine may increase the hypotensive activities of Rescinnamine.Approved
RamiprilRamipril may increase the hypotensive activities of Rescinnamine.Approved
RasagilineRasagiline may increase the hypotensive activities of Rescinnamine.Approved
RemikirenRemikiren may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Rescinnamine.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
RiociguatRescinnamine may increase the hypotensive activities of Riociguat.Approved
RituximabRescinnamine may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Rescinnamine.Approved, Investigational, Withdrawn
SacubitrilThe risk or severity of angioedema can be increased when Rescinnamine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Rescinnamine.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Rescinnamine.Approved
Salicylic acidThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Rescinnamine.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Rescinnamine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Rescinnamine.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Rescinnamine.Approved
SelegilineSelegiline may increase the hypotensive activities of Rescinnamine.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Rescinnamine.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Rescinnamine.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Rescinnamine.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Rescinnamine.Investigational
SildenafilSildenafil may increase the antihypertensive activities of Rescinnamine.Approved, Investigational
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Rescinnamine.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Rescinnamine.Approved, Investigational
SitaxentanRescinnamine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Rescinnamine is combined with Sodium aurothiomalate.Approved, Investigational
Sodium phosphateRescinnamine may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilSpirapril may increase the hypotensive activities of Rescinnamine.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Rescinnamine.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Rescinnamine.Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Rescinnamine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Rescinnamine.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Rescinnamine.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Rescinnamine.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Rescinnamine.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Rescinnamine.Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Rescinnamine.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Rescinnamine.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Rescinnamine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Rescinnamine.Experimental, Investigational
TemsirolimusThe risk or severity of angioedema can be increased when Temsirolimus is combined with Rescinnamine.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Rescinnamine.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Rescinnamine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Rescinnamine.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Rescinnamine.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Rescinnamine.Approved, Investigational
TetrahydropalmatineTetrahydropalmatine may increase the hypotensive activities of Rescinnamine.Investigational
TheodrenalineTheodrenaline may increase the hypotensive activities of Rescinnamine.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Rescinnamine.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Rescinnamine.Approved
TiboloneTibolone may increase the hypotensive activities of Rescinnamine.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Rescinnamine.Withdrawn
TimololTimolol may increase the hypotensive activities of Rescinnamine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Rescinnamine.Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Rescinnamine.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Rescinnamine.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Rescinnamine.Approved
TolonidineRescinnamine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Rescinnamine.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Rescinnamine.Approved
TorasemideTorasemide may increase the hypotensive activities of Rescinnamine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Rescinnamine.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Rescinnamine.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Rescinnamine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Rescinnamine.Approved, Investigational
TriamtereneTriamterene may increase the hyperkalemic activities of Rescinnamine.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Rescinnamine.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Rescinnamine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Rescinnamine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Rescinnamine.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Rescinnamine.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Rescinnamine.Investigational
Trolamine salicylateThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Trolamine salicylate.Approved
UdenafilUdenafil may increase the antihypertensive activities of Rescinnamine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Rescinnamine.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Rescinnamine.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Rescinnamine.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Rescinnamine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Rescinnamine.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Rescinnamine.Approved, Investigational
VincamineVincamine may increase the hypotensive activities of Rescinnamine.Experimental
VinpocetineVinpocetine may increase the hypotensive activities of Rescinnamine.Investigational
XipamideXipamide may increase the hypotensive activities of Rescinnamine.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Rescinnamine.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Rescinnamine.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Rescinnamine.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Rescinnamine.Approved, Investigational, Withdrawn
ZofenoprilZofenopril may increase the hypotensive activities of Rescinnamine.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Rescinnamine.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D00198
KEGG Compound
C06540
PubChem Compound
32681
PubChem Substance
46507786
ChemSpider
4444446
ChEBI
28572
ChEMBL
CHEMBL1668
Therapeutic Targets Database
DAP000910
PharmGKB
PA164768818
Wikipedia
Rescinnamine
ATC Codes
C02AA01 — RescinnamineC02LA02 — Rescinnamine and diureticsC02LA52 — Rescinnamine and diuretics, combinations with other drugs
MSDS
Download (52.7 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)238.5 °CPhysProp
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00349 mg/mLALOGPS
logP4.48ALOGPS
logP4.07ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)16.29ChemAxon
pKa (Strongest Basic)7.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area117.78 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity171.16 m3·mol-1ChemAxon
Polarizability69.65 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9604
Blood Brain Barrier+0.9248
Caco-2 permeable+0.6805
P-glycoprotein substrateSubstrate0.8163
P-glycoprotein inhibitor IInhibitor0.8826
P-glycoprotein inhibitor IINon-inhibitor0.6553
Renal organic cation transporterInhibitor0.5
CYP450 2C9 substrateNon-substrate0.8706
CYP450 2D6 substrateNon-substrate0.9064
CYP450 3A4 substrateSubstrate0.7223
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9144
CYP450 3A4 inhibitorNon-inhibitor0.8203
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7162
Ames testNon AMES toxic0.9208
CarcinogenicityNon-carcinogens0.9453
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8345 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.697
hERG inhibition (predictor II)Non-inhibitor0.678
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (13.2 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as yohimbine alkaloids. These are alkaloids containing the pentacyclic yohimban skeleton. The Yohimbinoid alkaloids contain a carbocyclic ring E arising through C-17 to C-18 bond formation in a corynantheine precursor.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Yohimbine alkaloids
Sub Class
Not Available
Direct Parent
Yohimbine alkaloids
Alternative Parents
Corynanthean-type alkaloids / Beta carbolines / Cinnamic acid esters / Coumaric acids and derivatives / 3-alkylindoles / Styrenes / Phenoxy compounds / Anisoles / Methoxybenzenes / Alkyl aryl ethers
show 16 more
Substituents
Yohimbine / Corynanthean skeleton / Yohimbine alkaloid / Pyridoindole / Beta-carboline / Cinnamic acid or derivatives / Coumaric acid or derivatives / Cinnamic acid ester / 3-alkylindole / Indole or derivatives
show 38 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Azhar I, Mazhar F, Manzar QN, Hussain I, Shamim S: Colorimetric determination of indolic drugs. Pak J Pharm Sci. 2005 Apr;18(2):48-51. [PubMed:16431399]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 06:46